Related Experiment Video

Updated: Aug 20, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Novel agents in epithelial ovarian cancer

Hui-Ti See1, John J Kavanagh

  • 1Department of Gynecologic Medical Oncology and Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

Cancer Investigation
|December 3, 2004
PubMed

Insights

New ovarian cancer therapies, including targeted agents and novel chemotherapies, show promise beyond the current taxane and platinum standard. Biomarker identification is key for predicting patient response and improving long-term survival.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • The current standard chemotherapy for ovarian cancer (taxane and platinum) has limited long-term efficacy, with high relapse rates and poor survival for advanced stages.
  • Ovarian cancer biology understanding has advanced, revealing molecular targets for novel therapeutic strategies.

Purpose of the Study:

  • To review emerging cytotoxic and targeted therapies for ovarian cancer.
  • To discuss the potential of new agents and biomarker-driven approaches to improve treatment outcomes.

Main Methods:

  • Review of current and investigational cytotoxic agents for ovarian cancer.
  • Evaluation of novel targeted therapies including small molecule inhibitors, monoclonal antibodies, antisense, and gene therapy.
  • Discussion of clinical trial data for these new therapeutic modalities.

Main Results:

  • Newer cytotoxic agents are under investigation, offering alternatives to the current standard.
  • Targeted therapies are entering clinical trials, showing potential for personalized ovarian cancer treatment.
  • Combination strategies of cytotoxic and targeted therapies are being explored.

Conclusions:

  • The development of novel cytotoxic and targeted therapies represents a significant advancement in ovarian cancer treatment.
  • Identifying predictive biomarkers is crucial for selecting patients likely to respond to these new agents and improving therapeutic success.

More Related Videos

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...